{"product_id":"collegiumpharma-soar-analysis","title":"Collegium Pharmaceutical SOAR Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Collegium Pharmaceutical SOAR Analysis gives you a clear framework for understanding the company's strengths, opportunities, aspirations, and results for research, strategy, investing, or business planning. The page already shows a real preview of the actual analysis, so you can see what the deliverable looks like before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Abuse-Deterrent Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's leadership in abuse-deterrent pain care rests on DETERx technology, which underpins Xtampza ER and helps set it apart from legacy opioid brands. In a roughly $2 billion branded chronic pain market, that positioning gives clinicians a clear option when they want an extended-release opioid with built-in abuse-deterrent design. The franchise's scale and focus make Collegium a category leader, not a broad pain player, and that sharper strategy supports durable share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Diversification via Accretive Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's acquisition-led play, anchored by Belbuca, has turned the Company into a broader, higher-margin pain franchise and cut its dependence on one product. In fiscal 2025, that mix helped support a double-digit net revenue CAGR over the prior three years while spreading clinical and pricing risk across more assets. The result is a more resilient revenue base and stronger cash generation from accretive M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormidable Managed Care and Payer Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Collegium Pharmaceutical kept 90%+ coverage across commercial and Medicare Part D plans, which supports steady volume and faster cash conversion. Its managed care team also holds exclusive or preferred positions with major payers, raising switching costs for smaller rivals and generic entrants. That access gives Company Name a rare edge in mid-sized specialty pharma: predictable reimbursement, durable formulary placement, and less price friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Efficiency and EBITDA Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical runs a lean model, with a specialized sales force of about 100 to 120 reps and automated supply-chain steps that keep costs low. Its adjusted EBITDA margin has stayed above 50 percent, showing that revenue converts to cash at a strong rate. That efficiency gives Company Name more dry powder to fund neurology pipeline expansion without heavy dilution or balance-sheet strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Liquidity and Balanced Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's strong liquidity and disciplined capital allocation stand out in fiscal 2025, with trailing free cash flow above $250 million giving it room to reduce debt and buy back shares at the same time. That mix supports EPS, trims leverage, and lowers enterprise risk, which is exactly what institutional investors want in a cash-generative specialty pharma name.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Strengths-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's High-Margin Pain Franchise Powers 2025 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's strength in fiscal 2025 came from DETERx-led abuse-deterrent pain care, with Xtampza ER and Belbuca driving a broader branded pain franchise.\u003c\/p\u003e\n\u003cp\u003eIt kept 90%+ commercial and Medicare Part D coverage, supported by exclusive or preferred payer access, which helped stabilize volume and cash flow.\u003c\/p\u003e\n\u003cp\u003eA lean 100-120 rep field force and adjusted EBITDA margin above 50% show a high-margin model that converted into more than $250 million of trailing free cash flow.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nAnalyzes Collegium Pharmaceutical's strengths, opportunities, aspirations, and results through the SOAR framework\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Collegium Pharmaceutical SOAR snapshot to quickly reduce strategy-planning blind spots and align strengths, opportunities, aspirations, and results.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into the Broader Neurology Sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's 2-brand pain platform can be a launch pad into epilepsy and migraine, where the global patient pools are far larger: about 50 million people live with epilepsy and about 1 billion with migraine. That breadth supports buying or launching mid-stage neurology assets that need stronger sales coverage. It also helps Collegium cut reliance on Schedule II products and lowers long-term regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExploiting Legacy Opioid Market Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTraditional opioids still face heavy litigation and tighter prescribing, so volume keeps shifting toward lower-risk, long-acting options. Collegium's differentiated pain portfolio is well placed to take share where clinicians want abuse-deterrent choices and steadier dosing. With U.S. opioid prescribing now far below its 2012 peak, even a flat market can still support organic growth for brands aligned with newer guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeveraging Data for Personalized Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital tools that track adherence and safety could help Collegium Pharmaceutical turn pain care into a data-backed service, not just a drug sale. U.S. chronic pain affects about 50 million adults, so even a small lift in persistence can support meaningful revenue and stronger prescriber retention. Partnerships that pair diagnostics with therapy can also help support higher reimbursement and stand out in a specialty market where tighter monitoring matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Geographic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical can extend its abuse-deterrent technology beyond the U.S. by licensing to regional partners in Europe and East Asia, where local commercialization would be costly. This asset-lite model would create royalty income without adding a full international sales force, which can lift returns on R\u0026amp;D spend. It also spreads fixed development costs across larger markets, improving margin quality if adoption follows U.S. demand patterns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation in the Mid-Market Specialty Space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWith several specialty pharma peers facing patent cliffs in 2026-2027, Collegium can act as a mid-market consolidator. Its investment-grade credit profile and cash generation support bolt-on buys of smaller orphan-drug portfolios. Those niche assets can bring high pricing power and long exclusivity, which helps reduce generic pressure and extend earnings visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Opportunities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's Next Growth Wave: Epilepsy and Migraine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical can grow beyond pain by using its 2-brand base to enter epilepsy and migraine, where patient pools are about 50 million and 1 billion. Its lower-risk pain mix also fits a market where U.S. opioid prescribing is still far below the 2012 peak, so share gains can come from safer, longer-acting products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e50 million patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigraine\u003c\/td\u003e\n\u003ctd\u003e1 billion patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic pain\u003c\/td\u003e\n\u003ctd\u003e50 million U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Collegium Pharmaceutical SOAR Analysis document you'll receive after purchase-no surprises, just the full professional report. The preview below is pulled directly from the complete file, so what you see is exactly what you'll get. Purchase unlocks the full, detailed SOAR analysis in its entirety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003espirations\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolution into a Diversified CNS Leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's board wants to move the Company beyond the \"pain company\" label and into a top-tier neuroscience player by 2030. Management's target is for non-opioid assets to drive 40% of portfolio revenue within four years, up from a mix still led by opioid brands in 2025. If it hits that shift, the Company should look less concentrated, which can help lower the cost of equity and broaden ESG-focused investor support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAchieving Long-Term Revenue Targets Toward $1 Billion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's leadership is aiming for $1 billion in annual net revenue, driven by volume growth and disciplined M\u0026amp;A. The plan depends on flagship brands holding peak share as the clinical and patent base matures, so the company is focused on the second half of the decade. That means closing any \"revenue holes\" before they open, not after.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSetting Industry Standards in Responsible Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Collegium Pharmaceutical's aspiration is to set the standard for responsible distribution through ethical, data-backed medication surveillance that helps flag misuse early. Its model depends on tight pharmacy and clinician coordination, plus safety controls that fit a specialty pain portfolio in a CNS market where reputational risk is high. By leading on surveillance and stewardship, Collegium aims to protect patients and its brand at the same time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReaching a Net-Zero Debt Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's FY2025 aim is to drive net debt-to-EBITDA below 1.0x while still funding buybacks, a balance sheet stance that would leave room for deals without new equity. In a mid-cap pharma name, that kind of leverage gives real optionality in downturns, when sellers often reset prices fast. The point is simple: lower debt, steady cash flow, and no need for dilutive raises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaximizing Long-Term Total Shareholder Return\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's aspiration is to land in the specialty pharma top decile for total shareholder return by pairing disciplined capital returns with clear operating updates. Frequent buybacks signal confidence, while crisp disclosure on clinical data and payer wins helps investors track execution. The goal is to keep management tied to long-term stock performance, not short-term noise.\u003c\/p\u003e\n\u003cp\u003eThat alignment can also support a more loyal institutional base, since shareholders can see how product uptake and reimbursement access feed into cash flow and capital return.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Aspirations-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Targets $1B Revenue and a Broader Neuroscience Future\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's FY2025 aspiration is to shift from an opioid-led model to a broader neuroscience company by 2030, with non-opioid assets reaching 40% of portfolio revenue. Management also wants $1 billion in annual net revenue and net debt to EBITDA below 1.0x, while still funding buybacks. The goal is simple: less concentration, more cash, and more deal room.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 aspiration\u003c\/th\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-opioid revenue mix\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual net revenue\u003c\/td\u003e\n\u003ctd\u003e$1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt to EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.0x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio shift\u003c\/td\u003e\n\u003ctd\u003eBy 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesults\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolidified Revenue Performance in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Collegium Pharmaceutical reported net product revenues in the $560 million to $585 million range, showing solid demand across its pain portfolio. The Belbuca acquisition was integrated effectively, and the asset helped support revenue stability. Hitting the high end of analyst expectations reinforced Collegium Pharmaceutical's buy-and-build strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompletion of Aggressive Capital Return Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Collegium Pharmaceutical completed its $150 million share repurchase program and cut diluted shares by several percentage points, directly lifting per-share value. That buyback helped offset higher research and development spending tied to pipeline assets. It shows management is still returning capital to shareholders while funding growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of Managed Care Preferred Positions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical expanded preferred formulary positions by 12% year over year, with 2026 audit results showing stronger managed care access. The win reflects account management's case that abuse-deterrent medicines can lower misuse risk and support better health-economic outcomes than standard alternatives. That access has helped protect net pricing power even as pharmaceutical inflation stayed elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Margin Maintenance Amidst Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn fiscal 2025, Collegium Pharmaceutical kept adjusted EBITDA margin at 52% even as it stepped up investment in neurology. That shows growth has not come at the cost of profit, and it points to tight cost control. Keeping overhead low while scaling also suggests a disciplined team that can absorb acquisitions and still protect cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt De-leveraging and Refinancing Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy early 2026, Collegium Pharmaceutical cut nearly $200 million of senior secured notes, a clear debt de-leveraging step that strengthened its credit profile. \u003c\/p\u003e\n\u003cp\u003eThat lower leverage should reduce the weighted average cost of debt and support net income through lower interest expense. \u003c\/p\u003e\n\u003cp\u003eAt 1.2x net debt-to-EBITDA, Collegium now sits among the strongest balance sheets in the Russell 2000 healthcare group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SOAR-Content-Results-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium boosts profit, buybacks, and debt reduction in fiscal 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Collegium Pharmaceutical delivered net product revenues of $560 million to $585 million and kept adjusted EBITDA margin at 52%, showing steady demand and tight cost control. The $150 million share repurchase program and nearly $200 million of senior secured note paydown boosted per-share value and cut leverage. Preferred formulary access rose 12% year over year, helping protect pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenues\u003c\/td\u003e\n\u003ctd\u003e$560M-$585M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e52%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare repurchases\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt paydown\u003c\/td\u003e\n\u003ctd\u003e~$200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SWOT Analysis Template","offers":[{"title":"Default Title","offer_id":57362823283070,"sku":"collegiumpharma-soar-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/9204\/3902\/files\/collegiumpharma-soar-analysis.webp?v=1777889813","url":"https:\/\/swot-analysis-template.com\/products\/collegiumpharma-soar-analysis","provider":"SWOT Analysis Template","version":"1.0","type":"link"}